Development of an RSV vaccine based on recombinant RSV-F expressed in mammalian cells and formulated in influenza virosomes

Schrift Standard Fett
Login

Forschungsstelle

INNOSUISSE

Projektnummer

8082.1;5 LSPP-LS

Projekttitel

Development of an RSV vaccine based on recombinant RSV-F expressed in mammalian cells and formulated in influenza virosomes

Projekttitel Englisch

Development of an RSV vaccine based on recombinant RSV-F expressed in mammalian cells and formulated in influenza virosomes

Texte zu diesem Projekt

	Deutsch	Französisch	Italienisch	Englisch
Kurzbeschreibung	-	-	-
Abstract	-	-	-

Erfasste Texte

Kategorie	Text
Kurzbeschreibung (Englisch)	Development of an RSV vaccine based on recombinant RSV-F expressed in mammalian cells and formulated in influenza virosomes
Abstract (Englisch)	Respiratory syncytial virus (RSV) is one of the most important causes of viral lower respiratory tract illness (LRI) during early childhood. Pevion Biotech has shown that the RSV-F protein, when reconstituted in virosomes, induces neutralizing anti-F antibodies and does not cause pathology in mice as observed with other vaccine candidates. However, the protein yield from virus is low and hampered by safety concerns. Here the the development of an RSV vaccine from recombinant F protein expressed in mammalian cells is proposed. The F protein will be purified and incorporated into virosomes, and the vaccine will tested in animals.

Kategorie

Text

Kurzbeschreibung
(Englisch)

Development of an RSV vaccine based on recombinant RSV-F expressed in mammalian cells and formulated in influenza virosomes

Abstract
(Englisch)

Respiratory syncytial virus (RSV) is one of the most important causes of viral lower respiratory tract illness (LRI) during early childhood. Pevion Biotech has shown that the RSV-F protein, when reconstituted in virosomes, induces neutralizing anti-F antibodies and does not cause pathology in mice as observed with other vaccine candidates. However, the protein yield from virus is low and hampered by safety concerns. Here the the development of an RSV vaccine from recombinant F protein expressed in mammalian cells is proposed. The F protein will be purified and incorporated into virosomes, and the vaccine will tested in animals.